


Edited by **Satya Prakash Gupta**

# Cancer-Causing Viruses and Their Inhibitors




**CRC Press**  
Taylor & Francis Group

Edited by **Satya Prakash Gupta**

National Institute of Technical Teachers' Training and Research (NITTTR), Bhopal, India

---

# Cancer-Causing Viruses and Their Inhibitors



**CRC Press**

Taylor & Francis Group

Boca Raton London New York

---

CRC Press is an imprint of the  
Taylor & Francis Group, an **informa** business

CRC Press  
Taylor & Francis Group  
6000 Broken Sound Parkway NW, Suite 300  
Boca Raton, FL 33487-2742

© 2014 by Taylor & Francis Group, LLC  
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper  
Version Date: 20140327

International Standard Book Number-13: 978-1-4665-8977-3 (Hardback)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies' printed instructions, and their websites, before administering any of the drugs recommended in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access [www.copyright.com](http://www.copyright.com) (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at  
<http://www.taylorandfrancis.com>

and the CRC Press Web site at  
<http://www.crcpress.com>

# Cancer-Causing Viruses and Their Inhibitors



---

# Preface

Cancer-causing viruses are also called oncoviruses or tumor viruses. Their infection in the human body leads to cancer. According to the World Health Organization Cancer Report 2008, cancer-causing viruses are responsible for up to 20% of cancer deaths all over the world; approximately 20%–30% of all cancers worldwide can be linked to viral infections. Cancer develops when cells start to divide uncontrollably because the “cell cycle machinery” that regulates this process stops working properly. These cancer cells can then invade other tissues. Cancer development is a complex process involving a series of genetic changes that disrupt the cell cycle machinery, interfering with cellular functions such as cell growth. Cancer-causing viruses play a key role in the development of certain cancers by contributing to these genetic changes. Although cancer itself is not an infectious disease, a significant number of human viruses have been linked to specific cancers, such as adult T-cell leukemia (ATL), hepatocellular carcinoma (HCC), Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC), posttransplant lymphomas, Hodgkin’s disease, cervical cancer, skin cancer in patients with epidermodysplasia verruciformis (EV), head and neck cancers, primary effusion lymphoma, and Castleman’s disease. The involvement of these viruses in human cancer development means that the frequency of these cancers can be reduced either prophylactically by vaccinating against the viruses or therapeutically by treating the infections. Extensive studies of these viruses are currently taking place with respect to their life cycle, their mechanism of infection, the inhibition of their growth, and the development of vaccines to treat the cancer caused by them. This book will cover in detail all of these aspects of oncoviruses, and it may be of great interest to medicinal and pharmaceutical chemists as well as to those working in the area of biotechnology. Cancer researchers may also find it of immense value.

There are a total of fourteen chapters in this volume. In the first chapter, Gupta and Gautam discuss the cancer-causing viruses discovered to date and include a brief description of their structure, genotypes, replication, and mechanisms of infection leading to cancers. The second chapter, by Yasunaga, presents the pathogenesis of human T-cell leukemia virus type 1 (HTLV-1) as well as current and upcoming therapeutic strategies against HTLV-1-mediated diseases. Chapter 3, by Deval and Huber, discusses the hepatitis C virus (HCV)—which leads to hepatocellular carcinoma—and its inhibitors. The number of HCV infection cases has now reached more than 170 million worldwide; one of the main protein targets for the generation of HCV therapeutics is the viral RNA-dependent RNA polymerase (RdRp) NS5B. This chapter summarizes what is known to date about the structure and function(s) of NS5B, with a particular focus on its role in HCV replication, and it reviews the recent advances in the development of nucleoside and nucleotide analogs as inhibitors of NS5B. Combination therapy utilizing interferon-alpha (IFN- $\alpha$ ), ribavirin (RBV), and a protease inhibitor is the current standard of care for HCV genotype 1 infection. In Chapter 4, Dash et al. discuss the hypothesis that a better understanding

of interferon's and ribavirin's HCV clearance mechanisms will lead to improvement in treatment response and will reduce the burden of liver cirrhosis and primary liver cancer. They present an overview of HCV infection clearance by treatment with type I and type III interferon (IFN), ribavirin, and other new emerging antivirals. Dash et al. also review novel antiviral strategies that aim to eradicate HCV infection and reduce the burden of liver cirrhosis and primary liver cancer. Like HCV, hepatitis B virus (HBV) is also a leading risk factor for hepatocellular carcinoma (HCC), with more than 80% of HCC cases occurring in regions that are also endemic for hepatitis B. In Chapter 5, Maiwall and Sharma discuss the factors associated with increased risk of developing HCC in chronic HBV-infected subjects and the preventive strategies for HBV-related HCC including the role of vaccination, nucleoside and nucleotide analogs, and interferon.

Epstein–Barr virus (EBV) is a ubiquitous pathogen that has adopted a unique and effective strategy for infection, persistence, and spread in its only biological host—human beings. It infects more than 90% of the human population worldwide and is associated with a diverse array of proliferative diseases in different parts of the world. It leads to BL, nasopharyngeal carcinoma (NPC), posttransplant lymphomas, and Hodgkin's disease. In Chapter 6, Jha et al. present the biology and pathophysiology of EBV and discuss currently available techniques for preventing EBV infection as well as for treating EBV-mediated malignancies.

More than four decades have elapsed since the initial hypothesis regarding the possible role of human papillomavirus (HPV) in the genesis of human cancers was postulated. It is now a matter of common knowledge that HPV infection accounts for almost 100% of cervical cancers and that HPV is responsible for 5.2% of all cancers including 25% of head and neck cancers. In Chapter 7, Chaudhury et al. present the structure and properties of HPV, its association with cervical and neck and head cancers, and the prevention and therapeutics of these cancers. Several recent studies have reported that high-risk HPVs are also present in human breast cancer tissues. Although several investigations did not confirm this fact, in Chapter 8, Al Moustafa presents an overview of the presence and role of high-risk HPVs in human breast carcinogenesis and focuses on the function of E5, E6, and E7 oncoproteins of high-risk HPVs in the progression of breast cancer.

Genital infection by HPV is the most common sexually transmitted disease in the world. Its global prevalence among women without cervical abnormalities is 12%. Chapter 9, by Cobucci et al., presents research data on promising prospective genital HPV infection therapies along with a brief description of current and future therapies.

Another of the viruses that infect humans, human herpesvirus 8 (HHV-8)/Kaposi's sarcoma-associated herpesvirus (KSHV), is described as a novel gamma-2 herpesvirus closely related to the human gamma-1 herpesvirus, Epstein–Barr virus (EBV). In Chapter 10, El Hajj et al. discuss the pathogenesis of HHV-8 and the treatment of the diseases associated with it, such as primary effusion lymphoma and Castleman's disease. Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the Herpesviridae virus family that infects humans. Although HSV-1 and HSV-2 are closely related, they differ in several aspects of their pathology. HSV-1 is primarily

associated with throat and mouth diseases as well as ocular and genital infections, while HSV-2 is the leading cause of recurring genital herpes cases worldwide. HSVs currently have no cure, and some have developed drug resistance. However, in Chapter 11, Chu et al. discuss the importance of tea polyphenolic compounds, such as epigallocatechin gallate (a green tea polyphenol) and theaflavin (a black tea polyphenol), against these HSVs.

People with AIDS have a weak immune system and thus are at an increased risk of developing infections, lymphoma, and other types of cancer. Therefore, HIV is also considered a cancer-causing virus. The most common types of AIDS-related cancers are Kaposi sarcoma and non-Hodgkin lymphoma. Other AIDS-related cancers include Hodgkin's disease and cancers of the lung, mouth, cervix, and digestive system. Anti-HIV drugs target multiple pathways in the life cycle of HIV and provide a large source of potential anticancer drugs. HIV integrase (IN) is one of the major viral targets for the development of new anti-HIV drugs. In Chapter 12, Garg and Ko have presented a review of HIV-related cancers and repositioning efforts to target some HIV IN inhibitors as anticancer agents as well as quantitative structure–activity relationship (QSAR) studies on HIV IN inhibitors that might be of great help in the design of more effective HIV IN inhibitors relevant to cancer treatment.

Oncolytic (tumor-killing) viruses vis-à-vis oncoviruses represent a heterogeneous group of viruses that have been observed/engineered to preferentially replicate in and destroy tumor cells but not normal cells. In Chapter 13, Vähä-Koskela et al. present a brief history of oncolytic viruses and their mechanism of action and clinical development. The authors assess whether there is any rationale—either molecular or immunological—for deliberate targeting of oncovirus-associated disease by oncolytic viruses. In this regard, they discuss a limited but expanding number of studies that indicate that it may be feasible to deliberately infect oncovirus tumors with oncolytic viruses and that such “virus wars” may result in substantial therapeutic benefit and long-term tumor control. Whereas oncolytic viruses have shown significant promise in cancer therapy, histone deacetylase inhibitors have also shown great promise for inhibiting cell proliferation in various cancer cell lines. Therefore, current research is directed toward combined use of these approaches. A detailed description of this aspect is presented by Patil and Gupta in Chapter 14.

In this volume, an attempt has been made to present a detailed account of cancer-causing viruses—their structure, genotypes, and replication; the mechanisms of infection leading to human cancers; modes of infection prevention; and the treatment of the cancers produced by these viruses. This book will be of great value to those working on virology and cancers and in the area of biotechnology as well as to general readers interested in viral infections. As the editor of this book, I have greatly enjoyed reading all the chapters and hope the readers do as well. I gratefully acknowledge the interest and zeal of all the authors for contributing such important, timely, and useful material for this book.

**Satya P. Gupta**

*National Institute of Technical Teachers' Training and Research (NITTTR)  
Bhopal, India*





---

# About the Editor

**Dr. Satya P. Gupta**, formerly a renowned professor of chemistry at Birla Institute of Technology and Science (BITS), Pilani, India, is presently a professor in the Department of Applied Science at the National Institute of Technical Teachers' Training and Research (NITTTR), Bhopal, India. Prior to this, he served as a distinguished professor in the Department of Pharmaceutical Technology at the Meerut Institute of Engineering and Technology (MIET), Meerut, India. Initially, he spent a few years at the Tata Institute of Fundamental Research (TIFR), Bombay, under Professor Girjesh Govil, where he worked on the structure and functions of biomembranes. He later moved to BITS, where he initiated work on the quantitative structure–activity relationship (QSAR), a very prominent area of medicinal chemistry. Dr. Gupta developed a deep understanding of QSAR, the modes of drug–receptor interactions, and the roles of physicochemical properties in drug–receptor interactions. Dr. Gupta earned an MSc in physical chemistry and PhD in quantum chemistry.

In 1985, Dr. Gupta was made a fellow of the National Academy of Sciences, India, and in 1989, he was awarded the coveted Ranbaxy Research Foundation Award. Dr. Gupta is one of the pioneers of QSAR. He has published approximately 200 papers in various journals of repute on the topic and has contributed dozens of authoritative reviews in prestigious journals such as *Chemical Reviews* (American Chemical Society), *Progress in Drug Research* (Birkhauser Verlag Basel), and *Current Medicinal Chemistry* (Bentham Science, the Netherlands and the United States). Dr. Gupta has also contributed several chapters in books produced by internationally reputed publishers such as J. R. Prous Science Spain, Elsevier Science BV (the Netherlands), Springer Heidelberg, and Springer Basel. He has edited several books published by Springer Heidelberg/Basel, namely, *Topics in Heterocyclic Chemistry*, Vol. 3 and 4 (2006); *Ion Channels and Their Inhibitors* (2011); *Matrix Metalloproteinase Inhibitors—Specificity of Binding and Structure–Activity Relationships* (2012); and *Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities* (2013). In addition, Dr. Gupta has been the editor-in-chief of four international journals published by Bentham Science: *Cardiovascular and Hematological Agents in Medicinal Chemistry*, *Current Computer-Aided Drug Design*, *Current Enzyme Inhibition*, and *Current Bioinformatics*. Dr. Gupta also serves on the editorial boards of several journals.

In 1996, Dr. Gupta's book, *Quantum Biology* (New Age International Publishers, New Delhi), was highly acclaimed by theoretical chemists and biologists. His recent book, *QSAR and Molecular Modeling* (published in 2011 by Anamaya, New Delhi, in collaboration with Springer, the Netherlands), has become the most popular volume among those interested in QSAR and molecular modeling—the most fascinating area of drug design. This book is a result of his vast work experience in QSAR.



---

# Contributors

**Sandra D. Adams**

Department of Biology and  
Molecular Biology  
Montclair State University  
Montclair, New Jersey

**Nilanjan Adhikari**

Natural Science Laboratory  
Division of Medicinal and  
Pharmaceutical Chemistry  
Department of Pharmaceutical  
Technology  
Jadavpur University  
Kolkata, India

**Ala-Eddin Al Moustafa**

Department of Oncology  
McGill University  
Montreal, Quebec, Canada  
and

Syrian Research Cancer Centre  
Syrian Society against Cancer  
Aleppo, Syria

**Luis A. Balart**

Department of Medicine  
Tulane University Health Sciences Center  
New Orleans, Louisiana

**Ali Bazarbachi**

Department of Internal Medicine  
Faculty of Medicine  
American University of Beirut  
Beirut, Lebanon

**Vincenzo Cerullo**

Immunovirotherapy Group  
Division of Biopharmaceutics  
and Pharmacokinetics  
University of Helsinki  
Helsinki, Finland

**Partha K. Chandra**

Department of Pathology  
Tulane University Health  
Sciences Center  
New Orleans, Louisiana

**Indranil Chatterjee**

Department of Surgical Oncology  
Saroj Gupta Cancer Centre and  
Research Institute  
Kolkata, India

**Susri Ray Chaudhuri (Guha)**

Drug Development, Diagnostics  
and Biotechnology Division  
CSIR–Indian Institute of Chemical  
Biology  
Kolkata, India

**Rahul Roy Chowdhury**

Department of Gynaecological Oncology  
Saroj Gupta Cancer Centre and  
Research Institute  
Kolkata, India

**Tin-Chun Chu**

Department of Biological Sciences  
Seton Hall University  
South Orange, New Jersey

**Ricardo Ney Oliveira Cobucci**

Department of Medicine  
Potiguar University  
Natal, Brazil

**Ana Katherine da Silveira Gonçalves**

Department of Obstetrics and  
Gynecology  
Federal University of  
Rio Grande do Norte  
Natal, Brazil

**Srikanta Dash**

Departments of Pathology and  
Medicine  
Tulane University Health Sciences Center  
New Orleans, Louisiana

**Janaina Cristiana de Oliveira Crispim**

Department of Pharmaceutical  
Sciences  
Federal University of Rio Grande  
do Norte  
Natal, Brazil

**Jerome Deval**

Alios BioPharma, Inc.  
San Francisco, California

**Hiba El Hajj**

Department of Internal Medicine  
Faculty of Medicine  
American University of Beirut  
Beirut, Lebanon

**Rajni Garg**

Computational Science Research  
Center  
San Diego State University  
San Diego, California

**Robert F. Garry**

Department of Microbiology  
Tulane University Health Sciences Center  
New Orleans, Louisiana

**Vertika Gautam**

Department of Chemistry  
University of Malaya  
Kualalumpur, Malaysia

**Satya P. Gupta**

National Institute of Technical  
Teachers' Training and Research  
(NITTTR)  
Bhopal, India

**Amit Kumar Halder**

Natural Science Laboratory  
Division of Medicinal and  
Pharmaceutical Chemistry  
Department of Pharmaceutical  
Technology  
Jadavpur University  
Kolkata, India

**Martin Huber**

Humapharm  
Liestal, Switzerland

**Tarun Jha**

Natural Science Laboratory  
Division of Medicinal and  
Pharmaceutical Chemistry  
Department of Pharmaceutical  
Technology  
Jadavpur University  
Kolkata, India

**Gene M. Ko**

Computational Science Research  
Center  
San Diego State University  
San Diego, California

**Fabrice Le Boeuf**

Centre for Innovative Cancer  
Research  
Ottawa Hospital Research Institute  
Ottawa, Ontario, Canada

**Lee H. Lee**

Department of Biology and Molecular  
Biology  
Montclair State University  
Montclair, New Jersey

**Rakhi Maiwall**

Assistant Professor of Hepatology  
Institute of Liver and Biliary Sciences  
New Delhi, India

**Raghida Abou Merhi**

Department of Internal Medicine  
Faculty of Medicine  
American University of Beirut  
Beirut, Lebanon

**Vaishali M. Patil**

Department of Pharmacy  
Bharat Institute of Technology  
Meerut, India

**Kurt Ramazan**

Department of Medicine  
Tulane University Health  
Sciences Center  
New Orleans, Louisiana

**Anirban Roy**

Drug Development, Diagnostics and  
Biotechnology Division  
CSIR–Indian Institute of  
Chemical Biology  
Kolkata, India

**Manoj Kumar Sharma**

Associate Professor of Hepatology  
Institute of Liver and Biliary Sciences  
New Delhi, India

**Snehasikta Swarnakar**

Drug Development, Diagnostics and  
Biotechnology Division  
CSIR–Indian Institute of Chemical  
Biology  
Kolkata, India

**Markus Vähä-Koskela**

Translational Virology Group  
Haartman Institute  
University of Helsinki  
Helsinki, Finland

**Jun-ichirou Yasunaga**

Laboratory of Virus Control  
Institute for Virus Research  
Kyoto University  
Kyoto, Japan



---

# Contents

Preface.....	vii
About the Editor.....	xi
Contributors .....	xiii
 <b>Chapter 1</b> Cancer-Causing Viruses: An Introduction .....	1
<i>Satya P. Gupta and Vertika Gautam</i>	
 <b>Chapter 2</b> Targeting Human T-Cell Leukemia Virus Type 1: Pathogenesis and Treatment Strategies .....	21
<i>Jun-ichirou Yasunaga</i>	
 <b>Chapter 3</b> Hepatitis C Virus and Its Inhibitors: The Polymerase as a Target for Nucleoside and Nucleotide Analogs .....	41
<i>Jerome Deval and Martin Huber</i>	
 <b>Chapter 4</b> Mechanisms of Hepatitis C Virus Clearance by Interferon and Ribavirin Combination: Lessons Learned from In Vitro Cell Culture .....	85
<i>Srikanta Dash, Partha K. Chandra, Kurt Ramazan, Robert F. Garry, and Luis A. Balart</i>	
 <b>Chapter 5</b> Hepatitis B Virus Infection and Hepatocellular Carcinoma .....	121
<i>Rakhi Maiwall and Manoj Kumar Sharma</i>	
 <b>Chapter 6</b> Epstein–Barr Virus and Treatment of Its Infection .....	157
<i>Tarun Jha, Amit Kumar Halder, and Nilanjan Adhikari</i>	
 <b>Chapter 7</b> Landscape of Papillomavirus in Human Cancers: Prevention and Therapeutic Avenues .....	207
<i>Susri Ray Chaudhuri (Guha), Anirban Roy, Indranil Chatterjee, Rahul Roy Chowdhury, and Snehasikta Swarnakar</i>	
 <b>Chapter 8</b> Role of High-Risk Human Papillomaviruses in Breast Carcinogenesis .....	243
<i>Ala-Eddin Al Moustafa</i>	



<b>Chapter 9</b>	Prospective Therapies of Genital Human Papillomavirus Infections .....	261
	<i>Ricardo Ney Oliveira Cobucci, Janaina Cristiana de Oliveira Crispim, and Ana Katherine da Silveira Gonçalves</i>	
<b>Chapter 10</b>	Human Herpesvirus Type 8/Kaposi Sarcoma Herpesvirus: An Overview of Viral Pathogenesis and Treatment of Associated Diseases .....	279
	<i>Hiba El Hajj, Raghida Abou Merhi, and Ali Bazarbachi</i>	
<b>Chapter 11</b>	Tea Polyphenolic Compounds against Herpes Simplex Viruses .....	321
	<i>Tin-Chun Chu, Sandra D. Adams, and Lee H. Lee</i>	
<b>Chapter 12</b>	HIV Integrase Inhibitors: Qualitative and Quantitative Structure–Activity Relationship Studies .....	345
	<i>Rajni Garg and Gene M. Ko</i>	
<b>Chapter 13</b>	Virus Wars: Oncolytic versus Oncogenic Viruses .....	407
	<i>Markus Vähä-Koskela, Fabrice Le Boeuf, and Vincenzo Cerullo</i>	
<b>Chapter 14</b>	Oncolytic Viruses and Histone Deacetylase Inhibitors .....	437
	<i>Vaishali M. Patil and Satya P. Gupta</i>	
<b>Index</b>	.....	467